)
Edge26 Jun 2026
The Universal Language: Inventing the Barcode
How lines in the sand on a Miami beach became the most scanned symbol in human history, and why it took decades for anyone to care.
Aquestive Therapeutics
Aquestive Therapeutics (AQST) investor relations material
Aquestive Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary26 Jun, 2026
Company overview and business model
Operates as a pharmaceutical company focused on innovative oral film drug delivery and proprietary products, as well as contract development and manufacturing for licensees.
Manufactures four commercialized products for licensees, with global reach and proprietary technologies such as PharmFilm®.
Pipeline includes Anaphylm™ (sublingual epinephrine film) and AQST-108 (topical epinephrine gel) targeting severe allergic reactions and dermatological conditions.
Maintains FDA-inspected manufacturing facilities in Indiana and headquarters in New Jersey.
Financial performance and metrics
Identified as a smaller reporting company, eligible for scaled disclosures until certain revenue or market cap thresholds are met.
Financial statements for 2024 and 2025 audited by KPMG LLP and incorporated by reference.
Use of proceeds and capital allocation
Will not receive proceeds from resale of warrant shares by selling stockholders, except for cash proceeds from warrant exercises.
Proceeds from warrant exercises, if any, will be used for general corporate purposes.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aquestive Therapeutics
- AQST-108, a topical epinephrine prodrug, advances to phase IIa for alopecia areata with strong data.AQST
Investor Day 202430 Jun 2026 - FDA progress, global expansion, and all proposals passed with strong shareholder support.AQSTAGM 202610 Jun 2026
- Q1 2026 revenue rose 66% to $14.4M, net loss narrowed, and key regulatory milestones advanced.AQSTQ1 202614 May 2026
- Virtual annual meeting to vote on directors, executive pay, and auditor ratification.AQSTProxy filing24 Apr 2026
- Stockholders will vote virtually on directors, executive pay, and auditor, focusing on governance and sustainability.AQSTProxy filing24 Apr 2026
- Anaphylm's NDA resubmission is on track for Q3, with launch prep backed by strong cash reserves.AQSTThe Citizens Life Sciences Conference 202610 Mar 2026
- Anaphylm targets Q3 2024 resubmission, with strong financials and market readiness.AQSTLeerink Global Healthcare Conference 20269 Mar 2026
- Anaphylm NDA resubmission set for Q3 2026; 2025 net loss $83.8M; 2026 revenue up to $50M.AQSTQ4 20255 Mar 2026
- Anaphylm sublingual film targets FDA approval in Q1 2027, aiming to disrupt the allergy market.AQSTOppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026
Next Aquestive Therapeutics earnings date
Q2 202611 Aug, 2026
Aquestive Therapeutics
Next Aquestive Therapeutics earnings date
Q2 202611 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage